GlassScriptPhysician profile
Seong Il Kim
NPI 1316987605
$13,564.94
in general payments reported to CMS, 2019-2025
79 companies · $233 in 2025
The $233 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,617 · 2020: $1,794 · 2021: $1,947 · 2022: $2,734 · 2023: $4,969 · 2024: $270 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,277 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,277.43 |
| Education | $194.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,034.21 | 2019-2023 | Opdivo, Opdualag |
| Exelixis INC. | $973.07 | 2019-2023 | Cabometyx |
| Amgen INC. | $870.62 | 2019-2023 | Kyprolis, Blincyto, Lumakras |
| Astrazeneca Pharmaceuticals LP | $850.81 | 2019-2025 | Calquence, Imfinzi |
| Incyte Corporation | $708.51 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Novartis Pharmaceuticals Corporation | $524.19 | 2019-2025 | |
| Pfizer INC. | $523.20 | 2019-2023 | |
| Genzyme Corporation | $451.73 | 2019-2023 | |
| Celgene Corporation | $448.60 | 2019-2023 | Opdualag, Reblozyl, Pomalyst |
| Karyopharm Therapeutics INC. | $445.76 | 2020-2023 | Xpovio |
| Seagen INC. | $439.68 | 2019-2023 | Adcetris, Tukysa, Tivdak |
| Bayer Healthcare Pharmaceuticals INC. | $419.55 | 2019-2024 | |
| Genentech USA, INC. | $372.54 | 2020-2023 | Venclexta, Phesgo |
| Glaxosmithkline, LLC. | $316.45 | 2020-2025 | Zejula, Jemperli, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $315.20 | 2019-2023 | Iclusig, Ninlaro, Alunbrig |
Show all 79 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seong Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.